Myelodysplasia clinical trials at UC Cancer

• A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS

  open to eligible people ages 18 years and up

  This study is being done to evaluate the safety and effectiveness of APTO-253 for the treatment of patients with the condition of acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) for which either the standard treatment has failed, is no longer effective, or can no longer be administered safely or poses a risk for your general well being.

  at UC Irvine UCLA

Last updated: December 16, 2019